Weight Loss Pills And Products Don't Work And Aren't Safe

Our ancestors lived in a feast or famine world. When you don't know where your next meal is coming from, or when it will arrive, the smart play is to pig out every time food is available. Our genes are programmed to extract as much energy as possible from what we eat and to store any extra energy in fat reservoirs, available in reserve for future famines. These deeply ingrained genetic tendencies worked great in the austere world of our ancestors, but are a disaster in our current world of refrigerators, ubiquitous fast food joints and milk shakes. Only one third of Americans are now able to maintain a normal weight; one third are overweight; and one third are obese. Excess weight is a risk factor for most illnesses, and for many people is also a consuming cosmetic concern. Pharma knows that a safe and effective diet pill would be one of its biggest potential cash cows. Over the past 80 years, drug companies have done extensive research and have developed many products trying to capture the enormous market of unsuccessful weight watchers. None have worked well; all have had considerable risks. But hope and hype always spring eternal. Dick Bijl is the perfect person to describe this troubling story and provide much needed cautions against our future credulity. He is president of the International Society of Drug Bulletins, representing 53 national drug bulletins, each engaged in evaluating the pluses and minuses of medications. Drug bulletins are essential-truthful antidote...
Source: Science - The Huffington Post - Category: Science Source Type: news

Related Links:

Authors: PMID: 30659135 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Chen YJ PMID: 30659134 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Dyer BA, Zamarin D, Eskandar RN, Mayadev JM Abstract Despite combined therapeutic approaches, there is an unmet clinical need to identify effective strategies for improved patient outcomes in treating locally advanced and metastatic cervical cancer (CC). Immunotherapy is emerging as a novel therapeutic approach in this disease for which the causative agent, human papillomavirus (HPV), has dynamic, complex immunomodulatory effects. This review explores the biologic rational of immuno-oncology in the treatment of CC and discusses the initial clinical efficacy, ongoing clinical trials, and rationale for combi...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Pennington KP, Urban RR, Gray HJ Abstract Minimally invasive surgery (MIS) was previously considered an acceptable alternative to open radical hysterectomy in the management of early-stage cervical cancer (ESCC), but adequately powered, high-quality prospective trials evaluating survival outcomes were lacking. Recently, a large randomized phase III trial, the Laparoscopic Approach to Cervical Cancer (LACC) trial, showed that MIS for ESCC is associated with a higher risk of recurrence and death compared with open surgery. We review the LACC trial findings in depth, as well as a recent National Cancer Databa...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL Abstract Cervical cancer is a malignant epithelial tumor that forms in the uterine cervix. Most cases of cervical cancer are preventable through human papilloma virus (HPV) vaccination, routine screening, and treatment of precancerous lesions. However, due to inadequate...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Conclusions: This systematic review shows that E-DATs are feasible to implement in cancer survivors. Future research should examine the optimal type, dose, and schedule of E-DATs for cancer survivors. PMID: 30659130 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Conclusions: Survival rates of patients with HER2+ breast cancer in our study are comparable to those seen in clinical trials. Our findings support chemotherapy de-escalation in patients with node-negative disease and validate the efficacy of FEC-DH in those with node-positive disease. PMID: 30659129 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Wang SY, Chen T, Dang W, Mougalian SS, Evans SB, Gross CP Abstract Background: Literature suggests that Oncotype DX (ODX) is cost-effective. These studies, however, tend to ignore clinical characteristics and have not incorporated population-based data regarding the distribution of ODX results across different clinical risk groups. Accordingly, this study assessed the cost-effectiveness of ODX across strata of clinical risk groups using population-based ODX data. Methods: We created state-transition models to calculate costs and quality-adjusted life years (QALYs) gained over the lifetime for women with es...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Wang Y, Yu X, Zhao N, Wang J, Lin C, Izaguirre EW, Farmer M, Tian G, Somer B, Dubal N, Schwartz DL, Ballo MT, VanderWalde NA Abstract Background: Chemotherapy with or without pelvic radiotherapy (RT) is included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for metastatic anal cancer (MAC), despite limited clinical evidence for RT in this setting. In addition, increasing evidence shows that local therapies, including RT, may increase patient survival for some types of metastatic cancers. The purpose of this study was to evaluate the patterns of care and association between definiti...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Conclusions: Although bisphosphonate use is recommended for all patients with newly diagnosed MM receiving antineoplastic therapy, 45% of patients in the United States did not receive this guideline-recommended care. PMID: 30659126 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
More News: Adipex | Alli | Arrhythmia | Brain | Brain Cancers | Bupropion | Burns | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cataracts | Children | Complementary Medicine | Diabetes | Diabetes Mellitus | Eating Disorders & Weight Management | Endocrinology | Ephedra | Gastroenterology | Genetics | Health | Heart | Heart Attack | Herbs | Hypertension | International Medicine & Public Health | Lessons | Liver | Meridia | Neurology | Nutrition | Obesity | Pharmaceuticals | Phentermine | Psychiatry | Pulmonary Hypertension | Science | Sports Medicine | Statistics | Sweeteners | Topamax | Training | Universities & Medical Training | Urology & Nephrology | Victoza | Websites | Weight Loss | Wellbutrin | Xenical